The findings suggested that the GLP-1 receptor agonist semaglutide was associated with a 40% to 70% reduced risk for first-time AD diagnosis, most strongly compared with insulin and most weakly compared with other GLP-1 receptor agonists. The gene discussed is INS; the disease is Alzheimer disease.